

[ After "Brief Description of the Drawings", please insert the following paragraph.

A2  
--In the following Figures, which further exemplify the claimed invention, dashed lines represent total white blood cell counts, as recorded on the right vertical axes. Black boxes represent BFUe as represented on the left vertical axes. Downward arrows represent points of administration of antibody. Horizontal axes represent days before and after first administration of antibody.--

[ Please delete Page 10, lines 21-33, to page 12 line 15, and insert therefor:

--Figure 1A is a profile of total white blood cells and CFU in peripheral blood before treatment of macaques.

Figure 1B is a profile of total white blood cells and CFU in peripheral blood of a baboon after treatment with anti-VLA-4 antibodies.

3  
Figure 1C is a profile of total white blood cells and CFU in peripheral blood of a macaque after treatment with anti-VLA-4 antibodies.

Figure 2 is a profile of total white blood cells and CFU in peripheral blood before treatment of an animal with the anti-CD18 monoclonal antibody 60.3. All symbols are as defined above.

Figure 3A is a profile of the results of combined treatment with G-CSF and anti-VLA-4 monoclonal antibody HP1/2. The symbols are as described above, except that narrow downward-pointing arrows represent points of G-CSF administration, bold downward-pointing arrows represent points of antibody administration, and dotted line (with triangles) represent total lymphocyte counts.

Figure 3B is a profile of the results for a control animal treated with GCSF alone.

Figure 4A shows high proliferative potential (HPP) progenitors (colonies over 0.5 mm in diameter of compact growth) resulting from combined treatment with GCSF and HP1/2 antibody.

Figure 4B is a profile of HPP progenitors resulting from treatment with GCSF alone. Symbols are as in Figure 3.

Figures 5A and 5B are  
A Figure 5 is the nucleotide sequences encoding the variable heavy region of the heavy and light chains of anti-VLA-4 murine monoclonal antibody HP1/2.